Conlin Alison K, Vahdat Linda
Division of Oncology, Department of Internal Medicine, New York-Presbyterian Weill Cornell Medical Center, New York, NY, USA.
Anticancer Res. 2006 May-Jun;26(3B):2279-80.
Ixabepilone is a new class of non-taxane microtubule-stabilizing agents. These agents bind tubulin, stabilize microtubules and, thus, block mitosis and result in cell death (1-8). In phase I studies, neutropenia was the only grade 4 toxicity while fatigue, anorexia and mucositis occurred as grade 3 toxicities. Neuropathy, myalgia, arthralgia, alopecia and gastro-intestginal toxicities also occurred at grades 1 and 2. No dermatological effects have been documented to date. Here, a case is reported of a 62-year-old woman with stage 4 breast cancer being treated with Ixabepilone (40 mg/m2) who developed a dermatological reaction not previously described as a toxicity from Ixabepilone therapy.
伊沙匹隆是一类新型的非紫杉烷类微管稳定剂。这些药物与微管蛋白结合,稳定微管,从而阻断有丝分裂并导致细胞死亡(1 - 8)。在I期研究中,中性粒细胞减少是唯一的4级毒性反应,而疲劳、厌食和粘膜炎则为3级毒性反应。1级和2级毒性反应还包括神经病变、肌痛、关节痛、脱发和胃肠道毒性。迄今为止,尚无皮肤学方面影响的记录。在此,报告1例62岁4期乳腺癌女性患者,接受伊沙匹隆(40 mg/m²)治疗,发生了一种此前未被描述为伊沙匹隆治疗毒性反应的皮肤学反应。